

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-14 (cancelled)

Claim 15 (original): An isolated cell line selected from the group consisting of ATCC No. PTA-4217, ATCC No. PTA-4218, ATCC No. PTA-4244, and ATCC No. PTA-4245, or progeny thereof.

Claims 16 - 26 (cancelled)

Claims 27-49 (not entered)

Claim 50 (new): An isolated antibody that binds to B7H3L comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4217.

Claim 51 (new): The isolated antibody of claim 50, wherein the isolated antibody is a humanized antibody.

Claim 52 (new): The isolated antibody of claim 50, wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and light chain variable regions of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4217.

Claim 53 (new): The isolated antibody of claim 52, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.

Claim 54 (new): An antigen-binding fragment of the isolated antibody of claim 50, wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a

F(ab')<sub>2</sub> and a Fv; and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4217.

Claim 55 (new): An isolated antibody that binds to B7H3L comprising a heavy chain variable region from the heavy chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4217.

Claim 56 (new): An isolated antibody that binds to B7H3L comprising a light chain variable region from the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4217.

Claim 57 (new): An isolated antibody that binds B7H3L comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4218.

Claim 58 (new): The isolated antibody of claim 57, wherein the isolated antibody is a humanized antibody.

Claim 59 (new): The isolated antibody of claim 57, wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and light chain variable regions of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4218.

Claim 60 (new): The isolated antibody of claim 59, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.

Claim 61 (new): An antigen-binding fragment of the isolated antibody of claim 57, wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab')<sub>2</sub> and a Fv; and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4218.

Claim 62 (new): An isolated antibody that binds to B7H3L comprising a heavy chain variable region from the heavy chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4218.

Claim 63 (new): An isolated antibody that binds to B7H3L comprising a light chain variable region from the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4218.

Claim 64 (new): An isolated antibody that binds B7H3L comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4244.

Claim 65 (new): The isolated antibody of claim 64, wherein the isolated antibody is a humanized antibody.

Claim 66 (new): The isolated antibody of claim 64, wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4244.

Claim 67 (new): The isolated antibody of claim 66, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.

Claim 68 (new): An antigen-binding fragment of the isolated antibody of claim 64, wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab')<sub>2</sub> and a Fv; and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4244.

Claim 69 (new): An isolated antibody that binds to B7H3L comprising a heavy chain variable region from the heavy chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4244.

Claim 70 (new): An isolated antibody that binds to B7H3L comprising a light chain variable region from the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4244.

Claim 71 (new): An isolated antibody that binds B7H3L comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4245.

Claim 72 (new): The isolated antibody of claim 71, wherein the isolated antibody is a humanized antibody.

Claim 73 (new): The isolated antibody of claim 71, wherein the isolated antibody is a chimeric antibody comprising a heavy chain variable region and a light chain variable region from the heavy chain and the light chain variable regions of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4245.

Claim 74 (new): The isolated antibody of claim 73, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.

Claim 75 (new): An antigen-binding fragment of the isolated antibody of claim 71, wherein the antigen-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab')<sub>2</sub> and a Fv; and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4245.

Claim 76 (new): An isolated antibody that binds to B7H3L comprising a heavy chain variable region from the heavy chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4245.

Claim 77 (new): An isolated antibody that binds to B7H3L comprising a light chain variable region from the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4245.

Claim 78 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4217 or progeny thereof, or an antigen-binding fragment thereof.

Claim 79 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4218 or progeny thereof, or an antigen-binding fragment thereof..

Claim 80 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4244 or progeny thereof, or an antigen-binding fragment thereof.

Claim 81 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4245 or progeny thereof, or an antigen-binding fragment thereof.

Claim 82 (new): A pharmaceutical composition comprising a therapeutically effective dose of the isolated antibody of claim 50 or an antigen-binding fragment thereof, together with a pharmaceutically acceptable carrier.

Claim 83 (new): The pharmaceutical composition of claim 82, wherein the composition comprises an additional therapeutic moiety.

Claim 84 (new): The pharmaceutical composition of claim 82, wherein the isolated antibody is linked to a therapeutic agent.

Claim 85 (new): A pharmaceutical composition comprising a therapeutically effective dose of the isolated antibody of claim 57 or an antigen-binding fragment thereof, together with a pharmaceutically acceptable carrier.

Claim 86 (new): The pharmaceutical composition of claim 85, wherein the composition comprises an additional therapeutic moiety.

Claim 87 (new): The pharmaceutical composition of claim 85, wherein the isolated antibody is linked to a therapeutic agent.

Claim 88 (new): A pharmaceutical composition comprising a therapeutically effective dose of the isolated antibody of claim 64 or an antigen-binding fragment thereof, together with a pharmaceutically acceptable carrier.

Claim 89 (new): The pharmaceutical composition of claim 88, wherein the composition comprises an additional therapeutic moiety.

Claim 90 (new): The pharmaceutical composition of claim 88, wherein the isolated antibody is linked to a therapeutic agent.

Claim 91 (new): A pharmaceutical composition comprising a therapeutically effective dose of the isolated antibody of claim 71 or an antigen-binding fragment thereof, together with a pharmaceutically acceptable carrier.

Claim 92 (new): The pharmaceutical composition of claim 91, wherein the composition comprises an additional therapeutic moiety.

Claim 93 (new): The pharmaceutical composition of claim 91, wherein the isolated antibody is linked to a therapeutic agent.